At the news
? NEUTRALIMPACT 2/10 144 filed Nov 12, 2026 at 16:04 ET
Director John W. Kozarich filed a Form 144 notice of intent to sell 500 shares of Ligand Pharmaceuticals common stock, with an estimated aggregate market value of approximately $162,500. The shares were acquired through stock awards in 2022 and 2025. This is a small, routine sale by a director and does not signal a material change in the company's outlook.
- Reporting person: John W. Kozarich, Director
- Securities to be sold: 500 shares of Common Stock
- Estimated aggregate market value: $162,500
- Shares acquired via stock awards on 02/28/2022 and 06/06/2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access